A Step Forward in Personalized Molecular Oncology – The Roma Study

The Era of Genetic Testing in Cancer

Many cancer patients and families now hear about genetic tests during treatment. Using blood or tumor tissue, these tests are ordered for different reasons, which can be confusing. They go beyond pathological examination to support personalized care. What do they offer, why are they important, when are they requested, and how do they guide treatment?

New developments aim to tailor personalized treatment to cancer biology. Research has increasingly explored how effectively these approaches improve quality of life. Roma is considered a milestone, and findings presented at the European Society for Medical Oncology (ESMO) 2024 annual meeting offer considerable hope for future treatment strategies.

What Do Genetic Tests Offer, and Why Are They Important?

Genetic tests clarify cancer biology and help identify personalized treatment options. By detecting tumor genetic changes, they indicate which treatments may be more effective. Inherited genetic tests assess predisposition, while genomic profiling supports targeted treatment. Biomarkers such as tumor mutational burden (TMB) and microsatellite instability (MSI) help assess sensitivity to immunotherapy, guiding suitable strategies and reducing adverse effects.

When Are They Requested?

Testing spans a broad range of situations: a family history, cancer at a young age, rare cancers, and advanced disease. For example, someone with several first-degree relatives affected by the same cancer is assessed for inherited predisposition. When specific mutations are identified, corresponding treatment options are considered.

How Do They Guide Treatment?

Genetic tests are used to identify the most effective cancer treatments. Inherited mutations guide early detection and risk reduction, while tumor genomic profiling guides targeted therapy. Immunotherapy sensitivity tests predict treatment activity, and cfDNA and ctDNA analyses monitor post-treatment recurrence to optimize care. Together, these tests personalize cancer treatment for better outcomes.

What Is Roma, and Why Does It Matter?

Conducted across 40 Italian centers and presented at ESMO 2024, Roma showed how integrating molecular tumor boards (MTBs) with comprehensive genomic profiling can help select personalized treatment.

• Molecular Tumor Board: Also known as an expert panel, it brings together specialists from different disciplines to review a case and choose the best personalized treatment. Molecular test results and clinical data guide its decisions.
• Comprehensive Genomic Profiling: This is essentially comprehensive genetic testing: this is the familiar term for a detailed genetic analysis that identifies changes in a patient's tumor. Its results are used to determine which treatment options may be most effective.

The expert panel explored critical questions: whom to profile, how to interpret results, and how to choose the best treatment for each case. Lead researcher Dr. Andrea Botticelli says this approach represents an important step toward improved outcomes.

Precision in Personalized Treatment Selection

Roma involved nearly 1800 patients with different solid (tissue/organ) tumors in a phase 2 randomized multibasket study. Patients with targetable molecular alterations were compared using targeted treatment (TT) selected by molecular tumor boards versus standard care. Case assessment used NGS technology within advanced genetic tests to perform molecular profiling of solid tissue and blood samples.

After MTB consultation, 400 patients were randomized: 200 to targeted treatment and 200 to standard care.

What Do the Results Mean?

• The primary endpoint was objective response rate, reported as 17%with targeted treatment and 9.5% with standard care.
• These findings indicate greater effectiveness with personalized treatment than with standard therapy.
• Median progression-free survival (PFS) was also longer with targeted treatment: 3.7 months versus 2.8 months with standard care.
• At 12 months, progression-free survival was 22.3% versus only 7.5%.

These data indicate an advantage in slowing cancer progression with targeted treatment.

Overall survival did not differ significantly, however. Serious adverse effects occurred in 35% receiving targeted treatment (particularly diarrhea and systemic infections) and 40% receiving standard care (neutropenia and fatigue). The difference was attributed to the different drugs used in each group.

The Role of Tumor Boards

A major innovation was MTB review of every patient. Botticelli notes that boards considered clinical characteristics, tumor histology, and potential resistance mechanisms alongside targetable alterations. This integrated approach may overcome limitations of earlier models and support more effective personalized treatment.

The Future of Personalized Oncology: Look Beyond the Mutation

Roma emphasizes the need for new models in personalized oncology. Strategies based on treatment-sensitive mutations may accelerate access and improve the chances of receiving effective treatment. As Dr. Federica Di Nicolantonio of the University of Turin points out, however, focusing only on mutation-based therapy is insufficient; tumor histology and other clinical factors must also be considered.

Conclusion: More Effective Cancer Management Through Personalized Treatment

Roma again demonstrated the importance of personalized cancer care. Selecting treatment according to molecular profiles could improve success even in advanced cancer. Developing targeted options represents a major step in personalized oncology and could play a critical role in improving future quality of life.

The study provides an important road map for understanding the future role of molecular oncology and personalized treatment. Its findings offer hope for wider use of personalized approaches in clinical practice.